Heliyon, Journal Year: 2024, Volume and Issue: 10(20), P. e39534 - e39534
Published: Oct. 1, 2024
Language: Английский
Frontiers in Cell and Developmental Biology, Journal Year: 2024, Volume and Issue: 12
Published: July 16, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty (NAFLD), is the most common disorder worldwide, with an estimated global prevalence of more than 31%. steatohepatitis (MASH), formerly (NASH), a progressive form MASLD characterized by hepatic steatosis, inflammation, and fibrosis. This review aims to provide comprehensive analysis extrahepatic manifestations MASH, focusing on chronic diseases related cardiovascular, muscular, renal systems. A systematic published studies literature was conducted summarize findings systemic impacts MASH. The focused association MASH metabolic comorbidities, cardiovascular mortality, sarcopenia, kidney disease. Mechanistic insights into concept lipotoxic inflammatory "spill over" from MASH-affected were also explored. are highly associated (50%-80%) other comorbidities such impaired insulin response, type 2 diabetes, dyslipidemia, hypertriglyceridemia, hypertension. Furthermore, 90% obese patients diabetes have Data suggest that in middle-aged individuals (especially those aged 45-54), independent risk factor for plays crucial role mediating pathological effects observed. Understanding multifaceted impact heart, muscle, early detection stratification. knowledge timely implementing management strategies addressing multi-organ involvement pathogenesis.
Language: Английский
Citations
26
Antioxidants, Journal Year: 2024, Volume and Issue: 13(8), P. 906 - 906
Published: July 26, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty (NAFLD), encompasses a range of conditions from steatosis to steatohepatitis (NASH). Its prevalence, especially among patients with metabolic syndrome, highlights its growing global impact. The pathogenesis MASLD involves dysregulation, inflammation, oxidative stress, genetic factors and, notably, mitochondrial dysfunction. Recent studies underscore the critical role dysfunction in MASLD's progression. Therapeutically, enhancing function has gained interest, along lifestyle changes and pharmacological interventions targeting processes. FDA's approval resmetirom for metabolic-associated (MASH) fibrosis marks significant step. While represents progress, further research is essential understand MASLD-related fully. Innovative strategies like gene editing small-molecule modulators, alongside interventions, can potentially improve treatment. Drug repurposing new targets will advance therapy, addressing increasing burden. Therefore, this review aims provide better understanding identify more effective preventive treatment strategies.
Language: Английский
Citations
14
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 9118 - 9118
Published: Aug. 22, 2024
The intricate interplay between the gut microbiota and polyphenols has emerged as a captivating frontier in understanding potentially harnessing therapeutic potential of these bioactive compounds. Phenolic compounds, renowned for their antioxidant, anti-inflammatory, antidiabetic, anticancer properties, are subject to transformations within milieu, where diverse microbial ecosystem exerts profound effects on metabolism bioavailability. Conversely, exhibit remarkable capacity modulate composition activity microbiota, fostering bidirectional relationship that extends beyond mere nutrient processing. This symbiotic interaction holds significant implications human health, particularly cardiometabolic diseases such diabetes mellitus, metabolic-dysfunction-associated steatotic liver disease, cardiovascular disease. Through comprehensive exploration molecular interactions, this narrative review elucidates reciprocal dynamics polyphenols, unveiling novel avenues intervention disorders. By unravelling cross-talk two entities, underscores multifaceted roles overall health pivotal role modulation promising strategy mitigating burden diseases.
Language: Английский
Citations
8
Metabolism and Target Organ Damage, Journal Year: 2025, Volume and Issue: 5(1)
Published: Jan. 21, 2025
In the present study by Dodig and colleagues, published in Metabolism Target Organ Damage , authors investigate role of insulin promoting type I collagen synthesis hepatic stellate cells (HSCs) through α5β1 integrin signaling. Using L-SACC1 transgenic mice, which exhibit hyperinsulinemia resistance without fasting hyperglycemia, researchers demonstrate that elevated levels significantly increase production HSCs. This effect is mediated signaling rather than PI3 kinase pathway. These findings suggest chronic may preprogram HSCs for enhanced fibrogenesis following liver injury, contributing to advanced fibrosis associated with metabolic disorders such as dysfunction-associated steatosis disease (MASLD) 2 diabetes. It further suggests increases risk significant burden disease. this commentary, strengths limitations are discussed, along potential impact these on current treatment strategies resistance, endogenous hyperinsulinemia, exogenous development MASLD progression fibrosis, cirrhosis, hepatocellular carcinoma.
Language: Английский
Citations
0
Lipids in Health and Disease, Journal Year: 2025, Volume and Issue: 24(1)
Published: Feb. 13, 2025
Language: Английский
Citations
0
Experimental and Clinical Gastroenterology, Journal Year: 2025, Volume and Issue: 9, P. 96 - 109
Published: March 6, 2025
Relevance. Metabolic-associated steatotic liver disease (MASLD) became the first pathology among all diseases with a tendency for further increase in incidence. Patients MASLD and normal weight are special cohort that is difficult to diagnose treat. The purpose: analyze literature about pathogenesis, prognosis of management lean patients MASLD. Materials methods. search devoted NAFLD or was conducted PubMed Google Scholar databases, these articles included adult body mass index less than 25 kg/m2 general population 23 Asian population. Discussion. observed mainly individuals obesity and/or type 2 diabetes mellitus, but 7%-20% have weight. This specific phenotype complex pathogenesis including visceral obesity, sarcopenia, genetic polymorphism, altered microbiota profile behavioral factors. Lean high prevalence metabolic disorders (arterial hypertension, dyslipidemia, mellitus) increased mortality from cardiovascular diseases, causes, compared healthy people. They can develop same spectrum damage (steatohepatitis, fibrosis, cirrhosis) as obesity. article describes diagnostic approaches people, requiring exclusion alternative causes steatosis, well risk groups identification. treatment challenges lack effective pharmacological therapy, necessity factors lifestyle modification. Conclusion. obtained data do not allow us consider benign disease. In this cohort, it necessary stage screen cardiometabolic early.
Language: Английский
Citations
0
International Journal of Endocrinology, Journal Year: 2025, Volume and Issue: 2025(1)
Published: Jan. 1, 2025
In 2023, the medical terminology for Nonalcoholic Fatty Liver Disease (NAFLD) and NA SteatoHepatitis (NASH) was updated to Metabolic Dysfunction‐Associated SteatoticLiver (MASLD) MA (MASH). This review highlights critical epidemiological, pathophysiological, therapeutic aspects of MASH, focusing on novel treatment option, resmetirom. Resmetirom, a thyroid hormone receptor‐beta (THR‐β) agonist, specifically targets liver function simulate localized hyperthyroidism, effectively reducing lipid accumulation fibrosis without systemic effects commonly associated with therapy. Clinical trials, particularly pivotal MAESTRO‐NASH trial, have demonstrated significant improvements in health metrics, achieving primary endpoints by resolving MASH worsening showing favorable safety profile. paper reviews mechanism action, efficacy, resmetirom, providing insight into its potential change landscape patients suffering from MASH.
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 4077 - 4077
Published: April 25, 2025
The recent introduction of the term metabolic-dysfunction-associated steatotic liver disease (MASLD) has highlighted critical role metabolism in disease’s pathophysiology. This innovative nomenclature signifies a shift from previous designation non-alcoholic fatty (NAFLD), emphasizing condition’s progressive nature. Simultaneously, MASLD become one most prevalent diseases worldwide, highlighting urgent need for research to elucidate its etiology and develop effective treatment strategies. review examines delineates revised definition MASLD, exploring epidemiology pathological changes occurring at various stages disease. Additionally, it identifies metabolically relevant targets within provides summary latest targeted drugs under development, including those clinical some preclinical stages. finishes with look ahead future therapy goal summarizing providing fresh ideas insights.
Language: Английский
Citations
0
Biomedicines, Journal Year: 2024, Volume and Issue: 12(7), P. 1444 - 1444
Published: June 28, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive fat accumulation in the liver. Intracellular oxidative stress induced lipid leads to various hepatocellular injuries including fibrosis. However, no effective method for mitigating MASLD without substantial side effects currently exists. Molecular hydrogen (H
Language: Английский
Citations
2
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(19), P. 10795 - 10795
Published: Oct. 8, 2024
The introduction of the term “Metabolic Steatotic Liver Disease” (MASLD) underscores critical role metabolic dysfunction in development and progression chronic liver disease emphasizes need for strategies that address both its comorbidities. In recent years, a liver-focused perspective has revealed altered endocrine function fatty is key contributor to dysregulation observed MASLD. Due secretory capacity, liver’s increased production proteins known as “hepatokines” been linked insulin resistance, explaining why MASLD often precedes other organs ultimately contributes systemic disease. Among these hepatokines, fibroblast growth factor 21 (FGF21) fetuin-A play central roles regulating abnormalities associated with MASLD, their dysregulated secretion response stress implicated This review postulates modulation by GLP1-Ras may mediate beneficial effects drugs, which have attention emerging pharmacotherapy By discussing crosstalk between GLP1-Ras-FGF21-fetuin-A, this hypothesizes possible novel GLP1-FGF21 dual agonist contribute management diseases. Although research needed go into details crosstalk, topic help researchers explore mechanisms type manage
Language: Английский
Citations
2